A comparative study on oncostatin M secretion by transplantable melanoma cells with regard to their biological properties and progression

• Autorzy: Kozlowska K , Zarzeczna M. , Cichorek M.
• Języki publikacji: EN

Abstrakty

EN

The authors have studied oncostatin M secretory activity of cells of two lines of transplantable melanoma with different biological properties. The level of OSM in melanoma cells supernatant was determined by ELISA test and OSM bioactivity was measured by using biotest line sensitive to OSM cytostatic activity — A 375 melanoma cells. OSM presence was confirmed in cellular lysates by western blot. It has been demonstrated that a spontaneous alteration of the transplantable melanotic melanoma line into an amelanotic line connected with tumour progression was accompanied by an increase of OSM release.

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2001
• Tom: 60
• Numer: 2
• Opis fizyczny: p.85-90,fig.,ref.

Twórcy

autor

Kozlowska K

• Medical University of Gdansk, Debinki 1, 80-210 Gdansk, Poland

autor

Zarzeczna M.

autor

Cichorek M.

Bibliografia

• 1. Bomirski A (1977) Biological properties of transplantable melanomas in the Syrian hamster during 16 years maintenance by serial passages. Acta Med Ged, Gdańsk.
• 2. Bomirski A, Kozłowska K, Żurawska-Czupa B (1975) An attempt to prepare nonenzymatically a simple cell suspension from solid transplantable melanomas. IX Int Pigment Cell Conf Houston Texas, 5–6 (Abstract).
• 3. Brown J, Rowe J, Liu J, Shoyab M (1991) Regulation of IL6 expression by oncostatin M. J Immunol, 197: 2175–2186.
• 4. Giavazzi R, Chirivi RGS, Garofalo A, Rambaldi A, Hemingway I, Pigott R, Gearing AJ (1992) Soluble intercellular adhesion molecule 1 is released by human melanoma cell and is associated with tumor growth in nude mice. Cancer Res, 52: 2628–2630.
• 5. Gibbs P, Chen Q, Robinson WA (1998) Effects of oncostatin M and tamoxifen on human melanoma cells. Melanoma Res, 8: 221–226.
• 6. Grant SL, Begley CG (1999) The oncostatin M signalling pathway : reversing the neoplastic phenotype? Mol Med Today, 5: 406–412.
• 7. Heymann D, Harb J, Ringeard S, Blanchard F, Lassort D, Raher S, Godard A (1996) Modulation of integrin alfa-v-beta-1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM). Bull Cancer, 83: 13–21.
• 8. Kerbel RS, Kobayashi H, Graham CH, Lu CH (1996) Analysis and significance of the malignant “eclipse” during the progression of primary cutaneous human melanomas. J Invest Dermatol Symp Proc, 1: 183–187.
• 9. Kobayashi H (1994) Variant sublines of early-stage human melanoma selected for tumorigenicity in nude mice express a multicytokine — resistant phenotype. Am J Pathol, 44: 776–786.
• 10. Kozłowska K, Cichorek M, Zarzeczna M (1999) Influence of transplantable melanomas on the secretion of cytokines by hamster peritoneal macrophages. Arch Imm Ther Exp, 47: 361–365.
• 11. Kozłowska K, Żurawska-Czupa B, Mierzewski P, Kostulak A (1980) Use of macrophages migration inhibition test to evaluate antigenic differences in golden hamster transplantable melanomas. Int J Cancer, 26: 211–215.
• 12. Laemmli UK (1970) Cleveage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227: 680–684.
• 13. Lazar-Molnar E, Hegyesi H, Toth S, Falus A (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12: 547–554.
• 14. Linsley PS, Bolton-Hanson M, Horn D, Malik N, Kallestad JC, Ochs V, Zarling JM, Shoyab M (1989) Identification and characterization of cellular receptors for the growth regulator, oncostatin M. J Biol Chem, 264: 4282–4289.
• 15. Lowry J, Rosenbrough N, Farr R, Randel R (1951) Protein measurement with the Folin phenol reagent. J Biol Chem, 19: 265–275.
• 16. Lu CH, Rak JW, Kobayashi H, Kerbel RS (1993) Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced — stage lesions. Cancer Res, 53: 2708–2711.
• 17. Malik N, Evans BE, Greenfield BW, Shapiro RA, Hanson M, Shoyab M (1994) Autocrine/paracrine induction of tissue inhibitor of metalloproteinase-1 in Chinese hamster ovary cells by oncostatin M. Matrix Biol, 14: 677–680.
• 18. McDonald VL, Dick K, Malik N, Shoyab M (1993) Selection and characterization of a variant of human melanoma cell line, A375 resistant to growth inhibitory effects of oncostatin M: coresistant to IL-6. Growth Factors, 9: 167–175.
• 19. Montero JFA, Brailly H, Sautes C, Joyeux I, Dorval T, Mosseri V, Yasukava K, Wijdenes J, Adler A, Gorin I, Fridman WH, Tartour E (1997) Characterization of soluble gp 130 released by melanoma cell lines: a polyvalent antagonist of cytokines from the interleukin 6 family. Clin Cancer Res, 3: 1443–1451.
• 20. Radka SF, Naemura JR, Shoyab M (1992) Abrogation of the antiproliferative activity of oncostatin M by a monoclonal antibody. Cytokine, 4: 221–226.
• 21. Revel M (1992) Growth regulatory functions of IL-6 and antitumour effects. Res Immunol, 143: 769–773.
• 22. Richards CD, Shoyab M, Brown TJ, Gaulide J (1993) Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol, 150: 5596–5603.
• 23. Silvani A, Ferrari G, Paonessa G, Toniatti C, Permiali G, Colombo M (1995) Down regulation of interleukin 6 receptor a chain in interleukin 6 transduced melanoma cell caused selective resistance to interleukin 6 but not to oncostatin M. Cancer Res, 55: 2200–2205.
• 24. Zarzeczna M, Kozłowska K, Cichorek M (1998) The release of TNF-a and IL-6 by transplantable melanoma melanocytes in regard to their progression. Polish Oncology, 1: 131–135.